Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

Hidden Complexities in the Measurement of Fructosyl-Lysine and Advanced Glycation End Products for Risk Prediction of Vascular Complications of Diabetes

  1. Naila Rabbani and
  2. Paul J. Thornalley⇑
  1. Clinical Sciences Research Laboratories, Warwick Medical School, University of Warwick, University Hospital, Coventry, U.K.
  1. Corresponding author: Paul J. Thornalley, p.j.thornalley{at}warwick.ac.uk.
Diabetes 2015 Jan; 64(1): 9-11. https://doi.org/10.2337/db14-1516
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Diabetes is associated with increased glycation of proteins by glucose and methylglyoxal (MG). Early-stage glycation by glucose forms fructosamine adducts, mainly Nε-fructosyl-lysine (FL), which can be exploited for assessment of glycemic control in the measurement of A1C (FL and Nα-fructosyl-valine). Later- or advanced-stage glycation processes involving degradation of FL and glycation of proteins by MG and related physiological dicarbonyl metabolites form advanced glycation end products (AGEs) (1). AGEs contribute to the pathogenesis of vascular complications of diabetes, and their measurement may provide improved complications-risk prediction.

Stable isotopic dilution analysis liquid chromatography-tandem mass spectrometry has markedly improved the measurement of AGEs, providing robust quantitation of multiple AGEs concurrently in tissues and body fluids (2). Examples of AGEs formed from fructosamine degradation are Nε-carboxymethyl-lysine (CML) and crosslink glucosepane, and examples of AGEs formed from MG are hydroimidazolone MG-H1 and Nε-(carboxymethyl)lysine (CEL). Liquid chromatography-tandem mass spectrometry also revealed two major forms of each AGE: AGE moieties of proteins, called AGE residues by conventional biochemical nomenclature (also known by the trivial nomenclature of “protein-bound AGEs”), and AGE free adducts (glycated amino acids) formed mainly by the proteolysis of AGE-modified proteins. Protein AGE residues have low renal clearance and biodistribution limited to that of the protein on which they are formed, whereas free adducts have high renal clearance and membrane permeability via amino acid and other transporters and are the major form in which AGEs are cleared from the body by urinary excretion (2). AGE assays that do not distinguish between protein AGE residues and AGE free adducts are difficult to interpret as they relate to unknown proportions and quantities of both—as applies to an often-used immunoassay for CML (3). Early assessments of AGEs were often limited to AGEs with intense intrinsic fluorescence, such as pentosidine (1). Pentosidine is produced mainly from pentose sugar precursors and is linked to pentose phosphate pathway activity (4). It is a covalent crosslink, but it has very low protein content compared with other crosslinks, such as glucosepane and nonglycation crosslinks of o,o’-dityrosine, Nε-(γ-glutamyl)lysine and others, suggesting it has limited functional or pathogenic effect in this role (2). Measurement of FL, MG-derived AGE, and pentosidine may provide biomarkers of glycemic control, MG metabolism, and pentose phosphate metabolism, respectively. As all are linked mechanistically to the development of vascular complications (5–7), this may provide a diagnostically powerful biomarker combination in diabetes. In this issue, this is addressed in measurements of plasma protein and skin collagen in the studies by Hanssen et al. (8) and Genuth et al. (9) (Fig. 1A).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Measurements of AGEs and association with the development of vascular complications of diabetes. A: Glycation adduct residues of plasma protein and skin collagen measured in studies of risk prediction models for vascular complications of diabetes. B: Biodistribution of FL and AGE residues in tissue and body fluids. Black arrows indicate flows of glycation adducts. Yellow block arrows show movement of plasma protein out of and into the plasma compartment by TER and tissue secretion, respectively, and glomerular filtration of FL- and AGE-modified albumin and FL and AGE free adducts with major recovery of albumin into the renal venous circulation by the albumin retrieval pathway and minor degradation by PTC proteolysis. PTCs, proximal tubular cells; RBCs, red blood cells.

Hanssen et al. (8) measured CML, CEL, and pentosidine residues of plasma protein of patients with type 2 diabetes (T2DM) and also computed an AGE residue content z-score. These were not correlated to A1C. In patients with type 1 diabetes (T1DM), however, we found plasma protein CML and pentosidine residue contents correlated positively with A1C and fasting plasma glucose, respectively (10). The link to glycemic control may be difficult to detect in a less metabolically homogenous study group of patients with T2DM. A higher AGE score was linked to low estimated glomerular filtration rate, low BMI, and low risk of peripheral artery disease (PAD). The low estimated glomerular filtration rate association is likely caused by decreased loss of FL- and AGE-modified albumin through the glomerular filter, and low BMI and PAD associations likely reflect increased transcapillary escape rate (TER) of albumin in obesity and PAD (11,12) (Fig. 1B). ACE inhibitors/angiotensin receptor blockers and lipid-lowering agents may similarly affect plasma protein AGE levels through effects on glomerular tightening and TER, respectively (13,14). These effects on plasma protein FL and AGEs have hitherto been given little consideration, except for two previous studies (13,15). In future work, awareness of these factors would likely improve risk predictor analysis. The positive association of plasma protein CEL with cardiovascular events is interesting, particularly with regard that expression of glyoxalase 1 (Glo1), which metabolizes MG (6), is a major driver for coronary artery disease (16).

Genuth et al. (9) measured furosine (an analytical surrogate of FL) and 6 AGE residues, fluorescence, acid solubility, and pepsin digestibility of skin collagen samples collected at closeout of the Diabetes Control and Complications Trial (DCCT), expanding the analyte panel studied previously. The 10 marker panel improved risk prediction of progression risk of retinopathy and neuropathy but not nephropathy, where glucosepane and MG-H1 emerged as principal new risk predictors. Increased furosine was associated with worsening of retinopathy, nephropathy, and neuropathy.

In the studies discussed, furosine and AGE residues were not analyzed in proteins at sites of complications. This disconnect may be sustained for the desired diagnostic application if there is a proportionate relationship between the change of glycating agent at the sites of complications development and plasma and skin samples analyzed. While associations of skin collagen furosine and AGEs with the development of complications remain after correction for A1C, there is a strong association of furosine with A1C (17). The FL and AGE residue content of proteins is related to the following factors: 1) concentration of glycating agent (glucose or MG, for example), 2) duration of exposure to the glycating agent, 3) intrinsic reactivity of the proteins toward glycation (as reflected in the rate constant kProtein, glycating agent), 4) chemical stability of the glycation adduct, and 5) residence time in the compartment of sampling. Furosine content may have improved risk predictive characteristics over A1C although both report on the same glucose glycation process because it provides a summation of glucose exposure over a greater time period than A1C due to the longer residence time of skin collagen than hemoglobin. Similarly, AGE residue contents of skin collagen, such as glucosepane and CML, may provide improved reporting on longer-term glucose exposure and “memory” of prior glucose exposures than A1C because of their higher chemical stability and residence time—the AGE content remaining even when glycemic control is improved (18).

Given the strengthening associations of increased exposure to MG with risk of microvascular and macrovascular complications (6,16), there is an unmet diagnostic need for the clinical equivalent of A1C for increased exposure to MG. MG-derived AGEs in hemoglobin are candidate biomarkers (10). The disconnect of increased Glo1 activity in red blood cells in diabetes (19) from decreased Glo1 activity at sites of complications (20), however, suggests that hemoglobin may not be the best place to look for MG exposure biomarkers in risk prediction of diabetes complications.

Article Information

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying articles, p. 257 and 266.

  • © 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

  1. ↵
    1. Rabbani N,
    2. Thornalley PJ
    . Glycation research in amino acids: a place to call home. Amino Acids 2012;42:1087–1096pmid:20981459
    OpenUrlCrossRefPubMed
  2. ↵
    Thornalley PJ, Rabbani N. Detection of oxidized and glycated proteins in clinical samples using mass spectrometry—a user's perspective. Biochim Biophys Acta 2014;1840:818−829
  3. ↵
    1. Zhang X,
    2. Frischmann M,
    3. Kientsch-Engel R,
    4. et al
    . Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients. Clin Chem Lab Med 2005;43:503–511pmid:15899672
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Wang F,
    2. Zhao Y,
    3. Niu Y,
    4. et al
    . Activated glucose-6-phosphate dehydrogenase is associated with insulin resistance by upregulating pentose and pentosidine in diet-induced obesity of rats. Horm Metab Res 2012;44:938–942pmid:23015612
    OpenUrlCrossRefPubMed
  5. ↵
    1. Nathan DM,
    2. McGee P,
    3. Steffes MW,
    4. Lachin JM,
    5. Grp DER,
    6. DCCT/EDIC Research Group
    . Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes 2014;63:282–290pmid:23990364
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Rabbani N,
    2. Xue M,
    3. Thornalley PJ
    . Activity, regulation, copy number and function in the glyoxalase system. Biochem Soc Trans 2014;42:419–424pmid:24646254
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Zhang Z,
    2. Yang Z,
    3. Zhu B,
    4. et al
    . Increasing glucose 6-phosphate dehydrogenase activity restores redox balance in vascular endothelial cells exposed to high glucose. PLoS One 2012;7:e49128pmid:23185302
    OpenUrlCrossRefPubMed
  8. ↵
    1. Hanssen NMJ,
    2. Beulens JWJ,
    3. van Dieren S,
    4. et al.
    Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL). Diabetes 2015;64:257−265
  9. ↵
    1. Genuth S,
    2. Sun W,
    3. Cleary P,
    4. et al
    .; The DCCT/EDIC Research Group. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes 2015;64:266−278
  10. ↵
    1. Ahmed N,
    2. Babaei-Jadidi R,
    3. Howell SK,
    4. Beisswenger PJ,
    5. Thornalley PJ
    . Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005;48:1590–1603pmid:15988580
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Dell’Omo G,
    2. Penno G,
    3. Pucci L,
    4. Mariani M,
    5. Del Prato S,
    6. Pedrinelli R
    . Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid metabolic syndrome. Atherosclerosis 2004;172:383–389pmid:15019550
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Kornerup K,
    2. Nordestgaard BG,
    3. Jensen TK,
    4. et al
    . Transendothelial exchange of low-density lipoprotein is unaffected by the presence of severe atherosclerosis. Cardiovasc Res 2004;64:337–345pmid:15485694
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Rabbani N, Adaikalakoteswari A
    , Rossing K, et al. Effect of irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. Amino Acids 2012;42:1627–1639pmid:21384133
    OpenUrlCrossRefPubMed
  14. ↵
    1. Dell’Omo G,
    2. Bandinelli S,
    3. Penno G,
    4. Pedrinelli R,
    5. Mariani M
    . Simvastatin, capillary permeability, and acetylcholine-mediated vasomotion in atherosclerotic, hypercholesterolemic men. Clin Pharmacol Ther 2000;68:427–434pmid:11061583
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Bent-Hansen L,
    2. Feldt-Rasmussen B,
    3. Kverneland A,
    4. Deckert T
    . Transcapillary escape rate and relative metabolic clearance of glycated and non-glycated albumin in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987;30:2–4pmid:3569694
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Mäkinen V-P,
    2. Civelek M,
    3. Meng Q,
    4. et al.,
    5. Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Consortium
    . Integrative genomics reveals novel molecular pathways and gene networks for coronary artery disease. PLoS Genet 2014;10:e1004502pmid:25033284
    OpenUrlCrossRefPubMed
  17. ↵
    1. Dyer DG,
    2. Dunn JA,
    3. Thorpe SR,
    4. et al
    . Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993;91:2463–2469pmid:8514858
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Lyons TJ,
    2. Bailie KE,
    3. Dyer DG,
    4. Dunn JA,
    5. Baynes JW
    . Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 1991;87:1910–1915pmid:1904067
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. McLellan AC,
    2. Thornalley PJ,
    3. Benn J,
    4. Sonksen PH
    . Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci (Lond) 1994;87:21–29pmid:8062515
    OpenUrlPubMed
  20. ↵
    1. Bierhaus A,
    2. Fleming T,
    3. Stoyanov S,
    4. et al
    . Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy [published correction appears in Nat Med. 2012;18:1445]. Nat Med 2012;18:926–933pmid:22581285
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Diabetes: 64 (1)

In this Issue

January 2015, 64(1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hidden Complexities in the Measurement of Fructosyl-Lysine and Advanced Glycation End Products for Risk Prediction of Vascular Complications of Diabetes
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hidden Complexities in the Measurement of Fructosyl-Lysine and Advanced Glycation End Products for Risk Prediction of Vascular Complications of Diabetes
Naila Rabbani, Paul J. Thornalley
Diabetes Jan 2015, 64 (1) 9-11; DOI: 10.2337/db14-1516

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Hidden Complexities in the Measurement of Fructosyl-Lysine and Advanced Glycation End Products for Risk Prediction of Vascular Complications of Diabetes
Naila Rabbani, Paul J. Thornalley
Diabetes Jan 2015, 64 (1) 9-11; DOI: 10.2337/db14-1516
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipose Tissue Malfunction Drives Metabolic Dysfunction in Alström Syndrome
  • Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.